AlphaLife Sciences Shares Insights on Generative AI in Clinical Development at JLABS Singapore Panel
Dec 12, 2024
In today’s dynamic clinical trial landscape, efficiency, precision, and scalability are no longer optional—they are critical drivers of success. Generative AI (GenAI) is emerging as a transformative force, reshaping the future of clinical research and development with its unparalleled ability to streamline processes and deliver actionable insights.
On December 5, 2024, Sharon Chen, Founder and CEO of AlphaLife Sciences, had the privilege of contributing to a prestigious panel discussion at JLABS Singapore. She joined an esteemed group of industry leaders:
- A/Prof Danny Soon, CEO of Consortium for Clinical Research and Innovation, Singapore (CRIS) and Executive Director of the Singapore Clinical Research Institute (SCRI).
- Dr. Huren Sivaraj, CEO and Co-Founder of Oncoshot.
Moderated by James Gallagher, Head of Early Innovation – Innovative Health, Global Development, Johnson & Johnson Innovative Medicine, and opened by Dr. Alessandro Falcone, MD, Head of JLABS Singapore, the panel explored "Harnessing AI and Digital Technology to Accelerate Clinical Development."
Sharon Chen shared her insights on:
🌟 Opportunities and Challenges: Addressing GenAI quality, fostering collaboration, and maximizing value realization.
🌟 Success Stories: Real-world examples of integrating GenAI into clinical workflows to deliver efficiency and quality.
🌟 Future Possibilities: How GenAI and digital solutions can redefine clinical research and create unprecedented value.
The panel highlighted the importance of data governance, streamlined workflows, and evolving regulations to enable impactful AI-driven advancements. They underscored collaboration between the life sciences industry and healthcare providers as essential to driving innovation.
We sincerely thank Dr. Alessandro Falcone, MD Falcone, Sharon Chan (Head of JLABS APAC), and the JLABS Singapore team for this valuable opportunity and wonderful event!
At AlphaLife Sciences, we are committed to leveraging GenAI to accelerate clinical development, improve efficiencies, and benefit patients worldwide.
